William Oh, MD
img_William Oh
CLINICAL PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
Specialties
Internal Medicine, Cancer (Oncology)

MD, New York University School of Medicine

Residency, General Practice, Brigham & Womens Hospital

Fellowship, Medical Oncology, Dana-Farber Cancer Institute

Certifications

American Board of Internal Medicine

Compassionate Caregiver of the Year, Kenneth B. Schwartz Center, Honorable Mention, 2003

Award Recipient, Loan Repayment Program for Clinical Research, NIH, 2004

Marquis Who’s Who in America, 2004-Present

Brigham/Harvard Business School Physician Leadership Program, 2007-2008

Patients Choice Award (vitals.com), 2008-2009

Excellence in Grand Rounds, Department of Medicine, MSSM, 2010

Election to the American Society of Clinical Investigation (ASCI), 2011

Fellow, American College of Physicians (FACP), 2013

Physician Honoree, Mount Sinai Prostate Cancer Center of Excellence, 2020

America’s Top Doctors for Cancer, 2010-2022

Top Doctors: New York Metro Area, 2010-2022

America’s Top Doctors, 2010-2022

New York Super Doctors, 2011-2022

New York Magazine “Best Doctors”, 2010-2022

Best Doctors in America, 2003-2022

Boston Magazine “Top Doctors”, 2005-2009

Newsweek, 2015

Election to Alpha Omega Alpha, 1992

Prize in Internal Medicine, NYU School of Medicine, 1992

ASCO/AACR Methods in Clinical Cancer Research Workshop, 1997

Dunkin Donuts Rising Stars Award, 2002-2003

Publications

Selected Publications

Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. George Mellgard, Vaibhav G. Patel, Xiaobo Zhong, Himanshu Joshi, Qian Qin, Bo Wang, Anish Parikh, Tomi Jun, Parissa Alerasool, Philip Garcia, Mahalya Gogerly-Moragoda, Amanda Leiter, Emily J. Gallagher, William K. Oh, Matthew D. Galsky, Che Kai Tsao. Journal of Cancer Research and Clinical Oncology

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De Santis, Ignacio Duran, Ross Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara A. Jereczek-Fossa, Rob Jones, Ravindran Kanesvaran, Pirkko Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel J. Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary Ellen Taplin, Derya Tilki, Levent Türkeri, Fabio Turco, Hiroji Uemura, Hirotsugu Uemura, Yüksel Ürün, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin. European Journal of Cancer

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. Bobby C. Liaw, Che Kai Tsao, Sonia Seng, Tomi Jun, Yixuan Gong, Matthew D. Galsky, William K. Oh. Oncologist

View All Publications

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC
William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer
William Oh, MD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Oh during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Archetype Therapeutics
  • Pfizer Pharmaceuticals
  • Sumitomo Pharmaceuticals, Osaka,Japan

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Sema4

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.